NCT00039182View on ClinicalTrials.gov

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

June 30, 2007

Conditions
Advanced Malignant MesotheliomaEpithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
Interventions
DRUG

erlotinib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00039182 - Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung | Biotech Hunter | Biotech Hunter